Developing molecules that individually harness the combined effect of
immune-mediated
and
direct anti-tumour activity

FIND OUT MORE GET IN TOUCH

Our Pipeline

iOnctura’s pipeline contains an exquisitely selective PI3Kδ small molecule inhibitor which has just entered a phase I clinical trial in solid tumours, a second generation selective ATX small molecule inhibitor that is in IND enabling studies and an early preclinical phase anti-CD73 antibody program.

our current projects

Pipeline

WHO WE ARE

MEET THE TEAM

HOW WE'RE FIGHTING CANCER

iOnctura is developing a pipeline of best in class molecules that harness the combined effect of immune-mediated and direct anti-tumour activity with an aim to deliver molecules with superior clinical efficacy and safety in oncology

MORE
Cancer Research UK Merck Dutch Cancer Institute
LATEST NEWS

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH